Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) – SEC staff letter
2026-03-19 · Re: · Accession 0000000000-26-002819 · 12 staff comment(s) issued
ASC 606: Revenue RecognitionMD&A: Results & Known TrendsR&D Expense DisclosureKPIs, Metrics & Earnings CallsBusiness Description (Item 101)IFRS & Foreign Private IssuersCapitalization, Equity & Escrow
2026-03-19 · · Comment 1 · B. Capitalization and Indebtedness, page 4 Awaiting / response not in dataset
Staff comment: We acknowledge your response to prior comment four. Please revise to address the following: • Revise the total capitalization amount in the table to reconcile to the balance sheet rather than using market capitalization; • Include a double line underneath the cash and cash equivalents and short-term investments numbers to distinguish them from the capitalization line items; and • Explain what the 'All other assets' line item represents and why it is included in the table. letter →
2026-03-19 · · Comment 2 · Item 4. Information on the Company, page 22 Awaiting / response not in dataset
Staff comment: We note that your January 12, 2026 press release announced a significant expansion of your VALLAURIX Research, Development and Innovation (RD&I) Centre in Singapore. With reference to Items 4.D. and 10.C. of Form 20-F, please revise to discuss this project and its impact or advise. letter →
2026-03-19 · · Comment 3 · Grow the Research and Development Capacities and Broaden Therapeutic Portfolio, page 27 Awaiting / response not in dataset
Staff comment: We note your response to prior comment 8, as well as the inclusion of the pipeline table appearing on page 28. In this regard: • We note that the row reflecting SCENESSE in adolescent EPP indicates that the next anticipated program milestone is a "filing in H2 2026." Please revise to clarify the relevant regulator or jurisdiction as appropriate. • Revise the row reflecting SCENESSE in adolescent and adult vitiligo to (1) clarify in a footnote or otherwise, that the ongoing Phase 3 CUV105 trial is evaluating SCENESSE with adjunctive phototherapy and not as a monotherapy and (2) to include the year in which you expect topline results from the CUV105 trial. • We note your disclosure on page 27… letter →
2026-03-19 · · Comment 4 · disclosure is a more appropriate place to discuss the PhotoCosmetics program. Awaiting / response not in dataset
Staff comment: We acknowledge your response to prior comment 11, which we reissue with respect to the bullet points below. In this regard, we note that your pipeline table should be a visual reflection of the narrative discussion in the prospectus, which discussion should provide proper context and thoroughly address all completed, ongoing, and planned preclinical and clinical trials of your material product candidates. • The pipeline table, and your narrative disclosure on page 28 regarding the expected marketing submission for NEURACTHEL in the EU, suggests that all clinical trials of NEURACTHEL for IS and MS are complete. However, it does not appear that the design of these clinical trials, or the… letter →
2026-03-19 · · Comment 5 · Page 3 Awaiting / response not in dataset
Staff comment: Please revise page 28 to disclose the jurisdiction(s) where you plan to apply for regulatory approval for SCENESSE in adolescent and adult vitiligo and in variegate porphyria, and, as appropriate, in which order. letter →
2026-03-19 · · Comment 6 · SCENESSE, page 28 Awaiting / response not in dataset
Staff comment: We note your statement that "[c]urrently, the largest market opportunity is seen in vitiligo..." To provide insight into the size of the market opportunity, please revise to discuss the estimated size of the vitiligo patient population in adolescents and adults worldwide and/or in markets that are material to your business prospects. Similarly, with respect to your late-stage NERUACTHEL program, provide the estimated size of the patient population with infantile spasms and acute exacerbations of MS, which you state you believe would benefit from NEURACTHEL treatment. letter →
2026-03-19 · · Comment 7 · Research and Development, page 46 Awaiting / response not in dataset
Staff comment: We acknowledge your response to prior comment 24 and partially reissue our comment. Please revise to disclose the following: • Whether you track your research and development costs by program area; and • As 'Other costs' is over 40% of 2025 research and development expense, please revise to quantify and disclose its components and whether this material trend is expected in future periods. letter →
2026-03-19 · · Comment 8 · Table of Contents, page F-1 Awaiting / response not in dataset
Staff comment: Please revise the table of contents to your Item 18 financial statements to address the following: • Revise to disclose the December 31, 2025 interim financial statements and notes thereto; and • Please distinguish that your interim financial statements are unaudited and presented on an IFRS basis, as opposed to your annual financial statements that are audited and presented on a U.S. GAAP basis. letter →
2026-03-19 · · Comment 9 · Revenue, page F-8 Awaiting / response not in dataset
Staff comment: We acknowledge your response to prior comment 23 and partially reissue our comment. Please revise your footnotes or MD&A to disclose the amounts for each significant category of sales rebate and other variable consideration adjustment reflected in the periods presented. letter →
2026-03-19 · · Comment 10 · periods presented. Awaiting / response not in dataset
Staff comment: We note your disclosure on page 35 that changes in pricing of SCENESSE, from which you have consistently generated over 90% of your product sales, may have a severe impact on your operations, that you do not offer rebates or discounts on SCENESSE beyond statutory requirements and that you aim for uniform pricing per jurisdiction. As it appears that uniform pricing may coexist with expected rebates and other variable consideration with EEA and U.S. national or private insurers, whether stated or implicit, tell us how you considered whether any non-uniform elements exist, and if so, whether they are variable consideration that should be estimated and constrained in determining your… letter →
2026-03-19 · · Comment 11 · Interim Condensed Financial Statements, page F-24 Awaiting / response not in dataset
Staff comment: Please revise your December 31, 2025 interim financial statements to include a header for each of the statements and notes that prominently include "IFRS" and "Unaudited" for immediate visibility to distinguish them from the U.S. GAAP annual statements. letter →
2026-03-19 · · Comment 12 · Notes to the Condensed Financial Statements, page F-28 Awaiting / response not in dataset
Staff comment: Please revise the basis of presentation footnote to include that these statements are prepared according to IFRS as issued by the IASB to qualify for the reconciliation exemption under Instruction 4 of Item 8.A.5 of Form 20-F. letter →
Full letter on EDGAR → · Filing index · All Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) correspondence
ASC 606: Revenue Recognition – what to check: Confirm each performance obligation, timing (point vs. over time) and significant judgments are disaggregated and explained, not boilerplate ASC 606 language.
MD&A: Results & Known Trends – what to check: Quantify drivers of changes (price vs. volume), discuss known trends and uncertainties, and avoid repeating the financial statements.
R&D Expense Disclosure – what to check: Break out R&D expense by program or product candidate (or explain why you cannot) in MD&A.
KPIs, Metrics & Earnings Calls – what to check:
Business Description (Item 101) – what to check:
IFRS & Foreign Private Issuers – what to check:
Capitalization, Equity & Escrow – what to check:
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)